Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Analyst Maintains Reduce Rating on bluebird bio and Downgrades Home Depot

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Finance_ Trading ratings today (2)
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

On March 5, 2024, Morten Herholdt, an analyst at HSBC, decided to maintain his Reduce rating on bluebird bio (NASDAQ:BLUE) while decreasing the price target from $2.31 to $1.02. This change was made after a thorough review of the company’s financial prospects. In a separate move, HSBC also downgraded Home Depot from a Hold to a Reduce rating, setting a new price target of $323.

BLUE Stock Plummets 2.24% Below 200-Day Moving Average on March 5, 2024

On March 5, 2024, BLUE stock experienced a decline in its performance, trading near the bottom of its 52-week range and below its 200-day simple moving average. The price of BLUE shares dropped by $0.03 since the market last closed, representing a 2.24% decrease. The stock closed at $1.53, and further dropped by $0.02 in pre-market trading.

BLUE Stock Analysis: Positive Growth in Revenue, Net Income, and EPS on March 5, 2024

On March 5, 2024, BLUE stock had a mixed performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was $3.60 million, which remained flat compared to the previous year. However, in the third quarter of the fiscal year, the total revenue surged to $12.39 million, marking a significant increase of 79.85% compared to the previous quarter.

The net income for BLUE showed improvement over the past year. The net income for the past year was -$266.58 million, but in the third quarter, it improved to -$71.73 million, representing a 67.47% increase compared to the previous year. Additionally, the net income increased by 1.61% since the last quarter.

Earnings per share (EPS) for BLUE also displayed positive growth trends. The EPS for the past year was -$3.39, but in the third quarter, it improved to -$0.66, marking a significant increase of 71.47% compared to the previous year. Furthermore, the EPS increased by 1.98% since the last quarter.

Overall, the financial performance of BLUE on March 5, 2024, showed positive improvements in total revenue, net income, and earnings per share compared to the previous year and the last quarter. Investors may view these positive trends as a promising sign for the company’s future growth and profitability. However, it is essential to conduct further analysis and research before making any investment decisions based on this information.

Tags: BLUE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Telecommunications Industry Stock Exchange

Analysts Remain Bullish on American Tower with Price Target Adjustments

CTVA stock news

Analyzing Array Technologies A Neutral Perspective

OHI stock news

Barclays Analyst Maintains EqualWeight Rating on Equinix Increases Price Target

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com